LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. 

Biotechnology

Education

LEXEO Therapeutics

R. Nolan Townsend

Julie Allen

Rand Monaghan

Emily H.

Amanda Wyatt Anderson

Jenny Speer

Leslie Dirisio

Jordan Dubow

Jenny Robertson

Richie Khanna

Ryan McHenry

Eric Adler

Keith Wonnacott

Ronald Crystal

Paul B. McCormac

The Research and Development team at LEXEO Therapeutics is responsible for pioneering and advancing gene therapy solutions to treat severe genetic and acquired diseases. This team conducts innovative research, develops and refines processes, ensures compliance with quality standards, and manages non-clinical and bioanalytical development. They collaborate closely to translate groundbreaking scientific discoveries into viable therapeutic products.

Research and Development

Clinical Development Team

Leadership Team

Research and Development

About

Team members

Other teams at LEXEO Therapeutics

Clinical Development Team

Leadership Team